The first day of new stock | HJ SCIENCE-B (06132) first listed in the morning with a flat opening. The company has three core products but has not yet obtained sales approval.

HJ SCIENCE-B (06132) made its debut on the market, with an offering price of HK$81.8 per share and a total of 13.6 million shares issued. Each lot consists of 100 shares, raising a net amount of approximately HK$1.019 billion. As of the time of writing, there has been no change in the stock price, which remains at HK$81.8, with a trading volume of HK$389 million. The prospectus states that HJ Future is a clinical-stage biotechnology company founded by industry experts dedicated to researching therapies for autoimmune, metabolic, and oncological diseases in 2017. The company owns three core products, HJ787, HJ178, and HJ891, all of which are self-developed, small molecule, Category 1 innovative drugs approved by the National Medical Products Administration of China. To date, the company has not received approval for commercial sales of any products nor generated any revenue from product sales. HJ Future has established a development platform for small molecule drugs, covering the entire process from drug design, efficient synthesis, screening and evaluation, pharmacological research, comprehensive CMC research, clinical strategy and operations, and translational medicine. On this platform, the company integrates computer simulation with experimental drug design and screening, targeted and rapid pharmacological evaluation, efficient CMC development, and clinical research. Through this integrated approach, the company has advanced multiple candidate drugs with significant differences in various therapeutic areas.